{
    "id": 28912,
    "fullName": "PTPRZ1 - MET",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PTPRZ1-MET results from the fusion of PTPRZ1 and MET, resulting in elevated Met and Stat3 signaling, increased cell proliferation, and greater tumor formation in xenograft models compared to control, leading to worse overall survival (PMID: 30343896). PTPRZ1-MET fusions are associated with glioma (PMID: 30343896).",
            "references": [
                {
                    "id": 12846,
                    "pubMedId": 30343896,
                    "title": "Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30343896"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5803,
        "geneSymbol": "PTPRZ1",
        "terms": [
            "PTPRZ1",
            "HPTPZ",
            "HPTPzeta",
            "phosphacan",
            "PTP-ZETA",
            "PTP18",
            "PTPRZ",
            "PTPZ",
            "R-PTP-zeta-2",
            "RPTPB",
            "RPTPbeta"
        ]
    },
    "variant": "PTPRZ1 - MET",
    "createDate": "11/16/2018",
    "updateDate": "12/03/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4233,
                "geneSymbol": "MET",
                "terms": [
                    "MET",
                    "AUTS9",
                    "c-Met",
                    "DFNB97",
                    "HGFR",
                    "RCCP2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15213,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Bozitinib (PLB-1001) in six of the evaluable secondary glioblastoma patients harboring PTPRZ1-MET, including one patient with both PTPRZ1-MET and MET del exon14, resulted in a partial response in two and stable disease in two, and in nine evaluable grade III glioma patients harboring PTPRZ1-MET, five demonstrated stable disease with treatment (PMID: 30343896; NCT02978261).",
            "molecularProfile": {
                "id": 30833,
                "profileName": "PTPRZ1 - MET"
            },
            "therapy": {
                "id": 7469,
                "therapyName": "Bozitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12846,
                    "pubMedId": 30343896,
                    "title": "Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30343896"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15212,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, astrocytic cells expressing PTPRZ1-MET demonstrated inhibition of Met and Stat3 phosphorylation when treated with Bozitinib (PLB-1001) in culture and in glioblastoma cell line xenograft models, Bozitinib (PLB-1001) treatment led to reduced tumor growth (PMID: 30343896).",
            "molecularProfile": {
                "id": 30833,
                "profileName": "PTPRZ1 - MET"
            },
            "therapy": {
                "id": 7469,
                "therapyName": "Bozitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12846,
                    "pubMedId": 30343896,
                    "title": "Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30343896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15214,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cell line xenograft models expressing PTPRZ1-MET treated with Xalkori (crizotinib) demonstrated inhibition of Met phosphorylation and increased phosphorylation of Cdk2, and reduced tumor volume, although to a lesser degree than when treated with Bozitinib (PLB-1001) (PMID: 30343896).",
            "molecularProfile": {
                "id": 30833,
                "profileName": "PTPRZ1 - MET"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12846,
                    "pubMedId": 30343896,
                    "title": "Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30343896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15303,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with secondary glioblastoma co-harboring PTPRZ1-MET and MET deletion exon 14 demonstrated a partial response when treated with Bozitinib (PLB-1001) (PMID: 30343896; NCT02978261).",
            "molecularProfile": {
                "id": 30967,
                "profileName": "PTPRZ1 - MET MET del exon14"
            },
            "therapy": {
                "id": 7469,
                "therapyName": "Bozitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12846,
                    "pubMedId": 30343896,
                    "title": "Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30343896"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30833,
            "profileName": "PTPRZ1 - MET",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30967,
            "profileName": "PTPRZ1 - MET MET del exon14",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}